Zelluna ASA是一家癌症治疗公司,执行10:1的反向份额分割,调整转让后的份额。 Zelluna ASA, a cancer therapy firm, executes a 10:1 reverse share split, adjusting shares post-transfer.

致力于"现成"TCR-NK细胞疗法的癌症治疗公司Zelluna ASA宣布以10:1的比例进行股权反向分割. Zelluna ASA, a cancer treatment company focusing on 'off the shelf' TCR-NK cell therapies, has announced a reverse share split at a 10:1 ratio. Radforsk Investeringsstiftelse与该公司的董事长Anders Tuv挂钩,将1 730份股份转给DNB银行ASA,以确保所有股份四舍五入到最近的全部份额。 Radforsk Investeringsstiftelse, linked to the company’s board chair, Anders Tuv, transferred 1,730 shares to DNB Bank ASA to ensure all shares are rounded up to the nearest whole share. 该公司定于2025年4月29日举行年度大会。 The company is scheduled to host an annual general meeting on April 29, 2025.